Qv Bioelectronics secures £100k for implanted brain tumour therapy device

Developing an implanted Electric Field Therapy device to treat glioblastoma, Nether Alderley-based Qv Bioelectronics has secured an estimated £100k in new funding. The company, which was incorporated in 2018, is currently focused on the clinical progression of its flagship product, GRACE.

The GRACE device is an implanted technology designed to deliver continuous, targeted electric fields to the site of a brain tumour. This therapy aims to disrupt the division of cancer cells, providing a treatment option intended to extend patient life expectancy and improve overall quality of life. The company operates from headquarters in Macclesfield and is categorized within the medical equipment manufacturing sector.

This latest £100k investment follows a series of larger capital raises. Qv Bioelectronics secured £1.4m in December 2025 and £680.7k in September 2025. Prior to these rounds, the company raised £2m in December 2022 and £250k in May 2023. Historical funding also includes a £595k round in June 2021 and a £180k round in May 2022. Early-stage valuations for the company were recorded at £1.3m in April 2021 and £1.2m in July 2020.

LinkedIn data indicates that the company currently has 18 employees. This contrasts with statutory accounts for the year ended 31 December 2024, which recorded one employee. The company is described as a venture capital-backed startup.

The documentation for this latest round was filed in May, following an allotment of shares in April. Total funding raised across the company's history now exceeds £5m, building on initial seed rounds of £25k and £50k completed in 2020.